/
CRBU
$1.77+$0.09 (+5.36%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$166.6M
99M shares
52-week range
$1.22 – $3.54
24% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.45%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-14.55
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $12.4M | $9.6M | $13.9M | $34.5M | $10.0M | $11.2M |
| Cost of revenue | $0 | $34.4M | $984.0K | $3.6M | $3.5M | $3.9M | $3.6M |
| Gross profit | $5.8M | −$22.1M | $8.6M | $10.2M | $31.0M | $6.1M | $7.5M |
| Gross margin | 100.0% | -178.5% | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| R&D | $23.6M | $34.4M | $52.3M | $82.2M | $112.1M | $130.2M | $109.4M |
| Operating income | −$34.3M | −$36.1M | −$67.0M | −$106.4M | −$116.1M | −$166.6M | −$136.2M |
| EBITDA | −$30.2M | −$35.2M | −$65.6M | −$95.7M | −$98.4M | −$145.2M | −$145.0M |
| Net income | −$23.4M | −$34.3M | −$66.9M | −$99.4M | −$102.1M | −$149.1M | −$148.1M |
| Net margin | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (diluted) | -0.85 | -1.24 | -1.11 | -1.64 | -1.38 | -1.65 | -1.59 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $26M | $-1.19 | $-1.47–$-0.84 | 4 |
| 2027 | $30M | $-1.42 | $-1.43–$-1.41 | 3 |
| 2028 | $35M | $-1.77 | $-2.22–$-1.34 | 4 |
| 2029 | $62M | $-2.40 | $-5.20–$-1.22 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Caribou Biosciences, Inc. Common Stock
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
www.cariboubio.com- Employees
- 97
- IPO / List date
- Jul 23, 2021
- HQ
- BERKELEY, CA
Held by traders on TradeandTell
No one on the platform currently holds CRBU.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,590,497 | $4.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRBU yet.
